Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Stella Hughes et al.|JAMA Neurology|2023Cited by 62
Updated Results of the COVID-19 in MS Global Data Sharing InitiativeSteve Simpson, Liesbet M. Peeters, Ashkan Pirmani et al.|Neurology Neuroimmunology & Neuroinflammation|2022Cited by 53
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Tomáš Kalinčík, Aysun Soysal et al.|JAMA Neurology|2025Cited by 43
Associations of DMT therapies with COVID-19 severity in multiple sclerosisSteve Simpson, Liesbet M. Peeters, Edward De Brouwer et al.|medRxiv|2021Cited by 28
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Helmut Butzkueven, Johannes Lorscheider et al.|Journal of Neurology Neurosurgery & Psychiatry|2022Cited by 17